Hookipa Pharma Inc (HOOK)

$0.85 -0.07 (-7.22%)
Market Cap 12.42M
Revenue (ttm) 43.95M
Net Income (ttm) -43.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -98.98%
Debt to Equity Ratio 0.00
Volume 108,536
Avg Vol 52,284
Day's Range N/A - N/A
Shares Out 12.06M
Stochastic %K 14%
Beta 0.78
Analysts Sell
Price Target $4.33

Latest News on HOOK

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Feb 20, 2025, 3:06 PM EST - 6 weeks ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

Jan 10, 2025, 2:00 AM EST - 2 months ago

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

HOOKIPA Pharma Inc - FORM 8 (OPD)

Jan 8, 2025, 11:23 AM EST - 3 months ago

HOOKIPA Pharma Inc - FORM 8 (OPD)

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Jan 7, 2025, 4:05 PM EST - 3 months ago

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Jan 6, 2025, 2:00 AM EST - 3 months ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Jan 2, 2025, 2:00 AM EST - 3 months ago

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Nov 11, 2024, 4:05 PM EST - 5 months ago

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Oct 31, 2024, 9:17 AM EDT - 5 months ago

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Oct 30, 2024, 7:30 AM EDT - 5 months ago

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Sep 24, 2024, 7:30 AM EDT - 6 months ago

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 7 months ago

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

HOOKIPA Pharma Announces Board of Directors Changes

Aug 30, 2024, 8:00 AM EDT - 7 months ago

HOOKIPA Pharma Announces Board of Directors Changes

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:57 AM EDT - 7 months ago

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 8, 2024, 4:30 PM EDT - 8 months ago

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Jul 22, 2024, 8:30 AM EDT - 9 months ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

Jul 8, 2024, 7:01 AM EDT - 9 months ago

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Jul 1, 2024, 4:31 PM EDT - 9 months ago

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

Jun 4, 2024, 1:00 PM EDT - 10 months ago

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

May 30, 2024, 4:30 PM EDT - 11 months ago

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

May 23, 2024, 5:01 PM EDT - 11 months ago

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 9, 2024, 7:01 AM EDT - 11 months ago

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Apr 25, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Apr 24, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts

Apr 22, 2024, 2:20 PM EDT - 1 year ago

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Apr 16, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

Apr 10, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 22, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Mar 6, 2024, 7:01 AM EST - 1 year ago

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Jan 29, 2024, 8:01 AM EST - 1 year ago

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Jan 16, 2024, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Dec 21, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Nov 20, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 9, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Nov 3, 2023, 12:01 PM EDT - 1 year ago

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Nov 2, 2023, 4:01 PM EDT - 1 year ago

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Oct 22, 2023, 6:01 AM EDT - 1 year ago

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Oct 18, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

HOOKIPA Announces Executive Leadership Change

Sep 13, 2023, 8:45 AM EDT - 1 year ago

HOOKIPA Announces Executive Leadership Change

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

HOOKIPA Pharma to participate in upcoming investor conferences in September

Sep 6, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma to participate in upcoming investor conferences in September

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 10, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

Aug 3, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2023, 5:00 AM EDT - 1 year ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

May 31, 2023, 9:30 PM EDT - 2 years ago

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

May 31, 2023, 4:45 PM EDT - 2 years ago

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 11, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

May 9, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

May 4, 2023, 7:02 AM EDT - 2 years ago

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

May 4, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

Apr 26, 2023, 11:30 AM EDT - 2 years ago

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO